Helicobacter pylori Diagnosis and Management

Gastroenterology Clinics of North America

Volumn 35, Issue 2, 2006, Pages 229-247

  Vilaichone, Ratha Korn ^a   Mahachai, Varocha ^b   Graham, David Y ^c,d  

^a THAMMASAT UNIVERSITY HOSPITAL   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACETYLSALICYLIC ACID; AMOXICILLIN; ANSAMYCIN DERIVATIVE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BISMUTH DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN DERIVATIVE; FURAZOLIDONE; LACTOFERRIN; MACROLIDE; METRONIDAZOLE; MUCOLYTIC AGENT; NITROIMIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROBIOTIC AGENT; PRONASE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; STOMACH SECRETION INHIBITOR; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; B CELL LYMPHOMA; BACTERIAL STRAIN; CHROMATOGRAPHY; CLINICAL PRACTICE; DIAGNOSTIC TEST; DIARRHEA; DISEASE ASSOCIATION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DUODENUM ULCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOASSAY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; MINIMUM INHIBITORY CONCENTRATION; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NAUSEA; PATIENT COMPLIANCE; PHOTOSENSITIVITY DISORDER; REVIEW; SOCIAL STATUS; STOMACH CANCER; STOMACH LYMPHOMA; STOMACH ULCER; TASTE DISORDER; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; UREA BREATH TEST; WESTERN BLOTTING;

ANTI-BACTERIAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PREVALENCE; PROTON PUMPS;

EID: 33746367451     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2006.03.004     Document Type: Review

References (89)

1. Munnangi S., and Sonnenberg A. Time trends of physician visits and treatment patterns of peptic ulcer disease in the United States. Arch Intern Med 157 13 (1997) 1489-1494
2. Steer H.W., and Colin-Jones D.G. Mucosal changes in gastric ulceration and their response to carbenoxolone sodium. Gut 16 8 (1975) 590-597
3. Steer H.W. The gastro-duodenal epithelium in peptic ulceration. J Pathol 146 4 (1985) 355-362
4. Steer H.W. Ultrastructure of cell migration through the gastric epithelium and its relationship to bacteria. J Clin Pathol 28 8 (1975) 639-646
5. Breuer T., Malaty H.M., and Graham D.Y. The epidemiology of H. pylori-associated gastroduodenal diseases. In: Ernst P., Michetti P., and Smith P.D. (Eds). The immunobiology of H. pylori from pathogenesis to prevention (1997), Lippincott-Raven, Philadelphia 1-14
6. Graham D.Y., Adam E., Reddy G.T., et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 36 8 (1991) 1084-1088
7. Everhart J.E., Kruszon-Moran D., Perez-Perez G.I., et al. Seroprevalence and ethnic differences in Helicobacter pylori infection among adults in the United States. J Infect Dis 181 4 (2000) 1359-1363
8. Malaty H.M., and Graham D.Y. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 35 6 (1994) 742-745
9. Hoang T.T., Bengtsson C., Phung D.C., et al. Seroprevalence of Helicobacter pylori infection in urban and rural Vietnam. Clin Diagn Lab Immunol 12 1 (2005) 81-85
10. Bodhidatta L., Hoge C.W., Churnratanakul S., et al. Diagnosis of Helicobacter pylori infection in a developing country: comparison of two ELISAs and a seroprevalence study. J Infect Dis 168 6 (1993) 1549-1553
11. Leal-Herrera Y., Torres J., Perez-Perez G., et al. Serologic IgG response to urease in Helicobacter pylori-infected persons from Mexico. Am J Trop Med Hyg 60 4 (1999) 587-592
12. Romero-Gallo J., Perez-Perez G.I., Novick R.P., et al. Responses of endoscopy patients in Ladakh, India, to Helicobacter pylori whole-cell and cagA antigens. Clin Diagn Lab Immunol 9 6 (2002) 1313-1317
13. Youn H.S., Baik S.C., Cho Y.K., et al. Comparison of Helicobacter pylori infection between Fukuoka, Japan and Chinju, Korea. Helicobacter 3 1 (1998) 9-14
14. Mahachai V., and Vilaichone R.K. Intrafamilial transmission of Helicobacter pylori in Thailand. Am J Gastroenterol 1006 9 (2005) Suppl:S133
15. Graham D.Y., and Malaty H.M. What remains to be done regarding transmission of Helicobacter pylori. Int J Epidemiol 31 3 (2002) 646-647
16. Shiotani A., and Graham D.Y. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med Clin North Am 86 6 (2002) 1447-1466
17. Censini S., Lange C., Xiang Z., et al. cagA pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci U S A 93 25 (1996) 14648-14653
18. Yamaoka Y., Kwon D.H., and Graham D.Y. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of Helicobacter pylori. Proc Natl Acad Sci U S A 97 13 (2000) 7533-7538
19. Vilaichone R.K., Mahachai V., Tumwasorn S., et al. Gastric mucosal cytokine levels in relation to host interleukin-1 polymorphisms and Helicobacter pylori cagA genotype. Scand J Gastroenterol 40 5 (2005) 530-539
20. Correa P., Haenszel W., Cuello C., et al. A model for gastric cancer epidemiology. Lancet 2 7924 (1975) 58-60
21. Correa P. Precursors of gastric and esophageal cancer. Cancer 50 11 Suppl (1982) 2554-2565
22. Correa P. The biological model of gastric carcinogenesis. IARC Sci Publ 157 (2004) 301-310
23. Graham D.Y., and Shiotani A. The time to eradicate gastric cancer is now. Gut 54 6 (2005) 735-738
24. In: Parkin D.M., Whelan S.L., Ferlay J., et al. (Eds). Cancer incidence in five continents, vol . VIII (2002), IARC Scientific Publications No. 155, Lyon (France)
25. Perrillo R.P., and Tedesco F.J. Gastric pseudolymphoma. A spectrum of presenting features and diagnostic considerations. Am J Gastroenterol 65 3 (1976) 226-230
26. Vanden Heule B., Van Kerkem C., and Heimann R. Benign and malignant lymphoid lesions of the stomach. A histological reappraisal in the light of the Kiel classification for non-Hodgkin's lymphomas. Histopathology 3 4 (1979) 309-320
27. Wotherspoon A.C., Ortiz-Hidalgo C., Falzon M.R., et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338 8776 (1991) 1175-1176
28. Parsonnet J., Hansen S., Rodriguez L., et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330 18 (1994) 1267-1271
29. Lee S.K., Lee Y.C., Chung J.B., et al. Low grade gastric mucosa associated lymphoid tissue lymphoma: treatment strategies based on 10 year follow-up. World J Gastroenterol 10 2 (2004) 223-226
30. Moayyedi P., Soo S., Deeks J., et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 25 1 (2005) CD002096
31. Howden C.W., and Hunt R.H. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 93 12 (1998) 2330-2338
32. Lane J.A., Murray L.J., Noble S., et al. Impact of Helicobacter pylori eradication on dyspepsia, health resource use, and quality of life in the Bristol Helicobacter Project: randomized controlled trial. BMJ 332 7535 (2006) 199-204
33. Graham D.Y. The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol 98 7 (2003) 1462-1470
34. Kaptan K., Beyan C., Ural A.U., et al. Helicobacter pylori-is it a novel causative agent in vitamin B12 deficiency?. Arch Intern Med 160 9 (2000) 1349-1353
35. Graham D.Y. Can therapy ever be denied for Helicobacter pylori infection?. Gastroenterology 113 6 Suppl (1997) S113-S117
36. Ofman J.J., Etchason J., Fullerton S., et al. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia: clinical and economic consequences. Ann Intern Med 126 4 (1997) 280-291
37. Nakayama Y., and Graham D.Y. Helicobacter pylori infection: diagnosis and treatment. Expert Rev Anti Infect Ther 2 4 (2004) 599-610
38. Graham D.Y., and Qureshi W.A. Markers of infection. Helicobacter pylori: Physiology and genetics. In: Mobley H.L.T., Mendz G.L., and Hazell S.L. (Eds) (2001), ASM Press, Washington DC 499-510
39. Vaira D., Malfertheiner P., Megraud F., et al. Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet 354 9172 (1999) 30-33
40. Windsor H.M., Abioye-Kuteyi E.A., and Marshall B.J. Methodology and transport medium for collection of Helicobacter pylori on a string test in remote locations. Helicobacter 10 6 (2005) 630-634
41. Graham D.Y., Kudo M., Reddy R., et al. Practical rapid, minimally invasive, reliable nonendoscopic method to obtain Helicobacter pylori for culture. Helicobacter 10 1 (2005) 1-3
42. El-Zimaity H.M., Segura A.M., Genta R.M., et al. Histologic assessment of Helicobacter pylori status after therapy: comparison of Giemsa, Diff-Quik, and Genta stains. Mod Pathol 11 3 (1998) 288-291
43. Laine L., Lewin D., Naritoku W., et al. Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. Gastrointest Endosc 44 5 (1996) 523-526
44. Graham D.Y., Opekun A.R., Hammoud F., et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 98 5 (2003) 1005-1009
45. Gisbert J.P., Gonzalez L., and Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori Eradication. Helicobacter 10 3 (2005) 157-171
46. Figura N., Crabtree J.E., and Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori. J Antimicrob Chemother 39 5 (1997) 585-590
47. Graham D.Y., Hammoud F., El-Zimaity H.M., et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 17 10 (2003) 1229-1236
48. Duck W.M., Sobel J., Pruckler J.M., et al. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg Infect Dis 10 6 (2004) 1088-1094
49. Watanabe K., Tanaka A., Imase K., et al. Amoxicillin resistance in Helicobacter pylori: studies from Tokyo, Japan from 1985 to 2003. Helicobacter 10 1 (2005) 4-11
50. van Zanten S.J., Goldie J., Hollingsworth J., et al. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol 45 3 (1992) 225-227
51. Dore M.P., Leandro G., Realdi G., et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 45 1 (2000) 68-76
52. Tytgat G.N. Treatments that impact favorably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 8 4 (1994) 359-368
53. Kwon D.H., Kim J.J., Lee M., et al. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 44 11 (2000) 3203-3205
54. Segura A.M., Gutierrez O., Otero W., et al. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 11 3 (1997) 529-532
55. van der Hulst R.W., Keller J.J., Rauws E.A., et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter 1 1 (1996) 6-19
56. Miehlke S., Mannes G.A., Lehn N., et al. An increasing dose of omeprazole combined with amoxicillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 11 2 (1997) 323-329
57. Fischbach L.A., Goodman K.J., Feldman M., et al. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 31 1 (2002) 128-139
58. Ford A., and Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved?. Can J Gastroenterol 17 Suppl B (2003) 36B-40B
59. Vakil N., Lanza F., Schwartz H., et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 20 1 (2004) 99-107
60. Moayyedi P., Feltbower R., Crocombe W., et al. The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. Aliment Pharmacol Ther 14 6 (2000) 719-728
61. Della Monica P., Lavagna A., Masoero G., et al. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 16 7 (2002) 1269-1275
62. Gene E., Calvet X., Azagra R., et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 17 9 (2003) 1137-1143
63. Fischbach L.A., van Zanten S., and Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 20 10 (2004) 1071-1082
64. Gisbert J.P., Khorrami S., Calvet X., et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists-their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 18 8 (2003) 757-766
65. Laheij R.J., Rossum L.G., Jansen J.B., et al. Evaluation of treatment regimens to cure Helicobacter pylori infection-a meta-analysis. Aliment Pharmacol Ther 13 7 (1999) 857-864
66. Broutet N., Tchamgoue S., Pereira E., et al. Risk factors for failure of Helicobacter pylori therapy:-results of an individual data analysis of 2,751 patients. Aliment Pharmacol Ther 17 1 (2003) 99-109
67. de Boer W.A., and Tytgat G.N. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?. Scand J Gastroenterol 30 5 (1995) 401-407
68. Graham D.Y., Osato M.S., Hoffman J., et al. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 14 2 (2000) 211-215
69. Canducci F., Cremonini F., Armuzzi A., et al. Probiotics and Helicobacter pylori eradication. Dig Liver Dis 34 Suppl 2 (2002) S81-S83
70. Di Mario F., Aragona G., Dal Bo N., et al. Use of bovine lactoferrin for Helicobacter pylori eradication. Dig Liver Dis 35 10 (2003) 706-710
71. Di Mario F., Aragona G., Bo N.D., et al. Use of lactoferrin for Helicobacter pylori eradication. Preliminary results. J Clin Gastroenterol 36 5 (2003) 396-398
72. Zullo A., De Francesco V., Scaccianoce G., et al. Quadruple therapy with lactoferrin for Helicobacter pylori eradication: a randomised, multicentre study. Dig Liver Dis 37 7 (2005) 496-500
73. Guttner Y., Windsor H.M., Viiala C.H., et al. Human recombinant lactoferrin is ineffective in the treatment of human Helicobacter pylori infection. Aliment Pharmacol Ther 17 1 (2003) 125-129
74. Fujii T., Iishi H., Tatsuta M., et al. Effectiveness of premedication with pronase for improving visibility during gastroendoscopy: a randomized controlled trial. Gastrointest Endosc 47 5 (1998) 382-387
75. Gotoh A., Akamatsu T., Shimizu T., et al. Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. Helicobacter 7 3 (2002) 183-191
76. Gurbuz A.K., Ozel A.M., Ozturk R., et al. Effect of N-acetyl cysteine on Helicobacter pylori. South Med J 98 11 (2005) 1095-1097
77. Zala G., Flury R., Wust J., et al. Omeprazole/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine. Schweiz Med Wochenschr 124 31-32 (1994) 1391-1397
78. Zullo A., Vaira D., Vakil N., et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 17 5 (2003) 719-726
79. Zullo A., Gatta L., De Francesco V., et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 21 12 (2005) 1419-1424
80. Francavilla R., Lionetti E., Castellaneta S.P., et al. Improved efficacy of 10-day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 129 5 (2005) 1414-1419
81. Hassan C., De Francesco V., Zullo A., et al. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy. Aliment Pharmacol Ther 18 6 (2003) 641-646
82. Nagahara A., Miwa H., Ogawa K., et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 5 2 (2000) 88-93
83. Treiber G., Ammon S., Schneider E., et al. Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 3 1 (1998) 54-58
84. Treiber G., Wittig J., Ammon S., et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 162 2 (2002) 153-160
85. Gisbert J.P., Marcos S., Gisbert J.L., et al. High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori eradication. Helicobacter 6 2 (2001) 157-162
86. Hopkins R.J. In search of the Holy Grail of Helicobacter pylori remedies. Helicobacter 6 2 (2001) 81-83
87. Bayerdorffer E., Miehlke S., Mannes G.A., et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 108 5 (1995) 1412-1417
88. Miehlke S., Kirsch C., Schneider-Brachert W., et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 8 4 (2003) 310-319
89. Miehlke S., Mannes G.A., Lehn N., et al. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 11 2 (1997) 323-329